Cadila. Z dus. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai [Listing Obligations and Disclosure Requirements] Regulations, 2015.

Size: px

Start display at page:

Download "Cadila. Z dus. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai [Listing Obligations and Disclosure Requirements] Regulations, 2015."

Peter Rich
5 years ago
Views:

1 Z dus Cadila Healthcare Limited November 3, 2018 Listing Department BOMBAY STOCK EXCHANGE LIMITED P J Towers, Dalal Street, Fort, Mumbai Code: Listing Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai Code: CADILAHC Re: Unaudited Financial Results for the guarter/ half year ended on Sgatember Dear Sir, Please find attached herewith the unaudited financial results for the qua rter/ half year ended on September 30, 2018, reviewed by the Audit Committee and taken on record by the Board of Directors today i.e. November 3, 2018 pursuant to Regulation No. 33[2][a] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, Please receive the same in order. Thanking you, Yours faithfully, For CADILA HEALTHCARE LIMITED UPEN H. SHAH COMPANY SECRETARY Encl.: As above Regd. Office : 'Zydus Tower', Satellite Cross Roads, Ahmedabad , lndia. Phone : (20 lines) CIN : L242306J1995PLCOZ5878

2 ' " Zydus Wfifl Cadila Healthcare Limited _ Registered Office: Zydus Tower, Satellite Cross Roads, Ahmedabad Tei. No.: (+9179) Fax No.: (+9179) /66 Website: CIN : L2423DGJ1995PLC Statement of Consolidated Results tor die Quarter and six Months Ended 30/09/2018 in Million Corrsponding 3 months Veer In rim Year to date Sr. No. Particulars ended guru hr flaws for the 1 Revenue 3 Months 30/09/2017 in 010 cum previous paiod Previous year ended 3 Months ended the previous period ended ended ended LL_ _M1_0_ M 40mm (mm4mm..wl m 8 Revenue from operations i ii Sales Other operating income 20,441 27,687 31,429 56,120 52, ,308 1,171 1, ,421 1,584 3,236 ili Total revenue from operations 29,612 28,937 32,219 58,549 54, ,544 b Other Income 304 1, , ,132 c Total manic 2 Explees 29,916 29,950 32,444 59,866 55, ,676 a b Cast of numeriais consumed Purchases of mintrade 6,583 6,329 5,865 12,012 11,078 25,733 4,651 4,414 4,596 9,065 9,665 19,141 c Changes In Inventors of finished goods, workinprogres and stockimam (1,315) (877) 497 (2,192) (1,538) (3,154) a Excise Duty on Sales 0 o o o (2 Employee bandits unease 5,212 5,266 4,636 10,478 8,975 18,545 f Finance costs g Depreciation and amusauon averse 1,475 1,418 1,263 2,093 2,479 5,388 y. om, W 7,603 7,355 8,054 14,950 14,554 30,809 I Tobi um 24,566 24,255 25,316 48,021 46,331 97,368 3 Profit More ml 1100, Ill and share 0' MI [lou] ofjoint venturs (12) 5,350 5,695 7,128 11,045 8,671 23,308 4 Emma items mm radon in and mm or profit] [1000] «Joint vermin: (34) 5,350 5,695 7,128 11,045 8,671 23,308 6 Tax averse a b C Current tax Deferred tax Tomi Bx expenss 1,951 1,193 1,820 3,144 2,583 6,436 (704) (694) (167) (792) 1,247 1,203 2,123 2,450 2,416 5,644 7 PM! share d profit] [bu] 0710M! ventures (56) 4,103 4,492 5,005 8,595 6,255 17,664 8 Share of WW venture (net 01 tax) '41 Profit More NonWWII 1m (7+8) 4,282 4,672 5,131 8,954 6,583 18, NonControlling Intersrs Id M on: ma, MaiCum 1am an Inn. at Mt] (I000) 191de mu nun eominulng optltiane (910) 4,175 4,605 5,038 8,780 6,421 17, a Profit/(ids) before tax from discontinued operations 0 0 (5) 0 (4) (188) Tax expense 01 discontinued operations 0 0 O c Profit/(loss) any tax from Discontinued operations 0 0 (5) 0 (4) (188) 13 Net Profit lo: the period] yur (11412) 4,175 4,605 5,033 0,700 6,417 17, other Cornprdlensive Income (0C!) a I Iheiristnatwiilnotberedawfledmpmntorioss: ' lie measurement gains/ (loss) on post empioyment defined benefit plans (28) (39) (139) (87) (192) (151) II Net Galn/ (Loss) on Fair value enough or: Equity Securities 45 (127) 96 (02) in iv b Income tax effect on above items Total ItentsmatwillberedasiflederWorkm: (159) 2 (137) i Exchange differences on narrsiauon of forum operafions (1,647) (1,017) (137) (2,664) 79 (132) II on offureiw rising on redassifled 00 sraiemeni or Prom and Loss 0 o o o o (18) Ill iv Income tax died on above mms Total (1,647) (1,017) (137) (2,864) 79 (150) c Shareofoflofjointveimiismaonax) d Other Comprehensive Income, net of tax (1,625) (1,176) (135) (2,001) Total Comm Income ( ) 2,657 3,496 4,991 6,153 6,860 18, Total Comprehensive Income : Owners of the Company NonCormoIIIriq Interests 2,550 3,429 4,898 5,979 6,698 17, Paidup equity share capital (Face value Re. 1/) 1,024 1,024 1,024 1,024 1,024 1, Raerves arciuding Revaluation Rserve as per balance sheet 0' previous accounting year (Le. Other Equity) 19 A Earnings per Illere lor continuing operations (not annuallsed) 36,421 a Basic (115.) b Diluted (in) I no more ror a Basic (95.) b Dilwed (m) (not. C E,. 0U share For I (M ) (0.00) (0.00) (0.00) (0.18) (0.00) (0.18) a Basic (Rs) b Diluted (Rs)

3 [I] mmmwmtwnm/uxmmmwmmummievvedbymemmnmmmmz,lexsmnuwwmummmwmemumn [1] [3] [4} [51 [6] [7] [5! mmrunmma,zom mmmdflmmmfldma"umw dwwm WWHO MSEBI[WWflWW]W,ZOIS mmmmwmm wmm13,20mmm:company,mmmmwmmwmwmmnmmmwmmsmmmmm mummywe:mmmmmmdmwwmmmmmn,2018,mmmtocsrwsmwmnm. mmmmmwmzmmum,amdnwwmmmmomz4.2013mmuaulmummunm,nsmamofmm. Emma/owl1,20w,meammnsmpmImAsns,"Rmhomunuacsmmom,mummmmmmsmeMthmWsdwLulam, WWWMNWWWMMMWMWJMWdIMBIISfiMMnmynmlnmmmemeMOmDw, mmulmmumumvnmmmmmmw1,2017mmcmmmmvmmmmm.nwmmmu,mmmmmm mummmnzolasmmdm.mmmmmmmeso,2017mmmdmm,m5mmhcfi mmmmflkhmmmwb.wwmm IWMS&M12,500,001emflymofBawlydsmmmumflmmmwfiulflhwm1m.LINMIWWIMIN, zommmmmdwmvmmmwnmmmmmbayaw,1umzs,2on. mmnmmmmwwmn,zoxsruomgmnawmm,mwmm,lmrnnmmmcmwmwmm uw,mrmmmwmmsswns1mmmumziplmmmummmmmmmmmmmmsmmmmmmmmmwm,murmur) mmwlsxos vmwmmmsnmww'mammmlllanm2013,mmmdmmmswmw wwmmmmwmm31,20m,opemmsofaremrovtheoremsmmmwmmmdmmmmmm'm/[mlmnm W. [9] mummmmmwmmmwmmmmwmamzmwm [10] mmmmwdqu mmi [11] MWWMRMMMWSW: [m,m.m].mmmmmmfls o! m: Compmy I! as hm: m h In "w" W 3m V. In4 Vet D 6m M mu a: has for m: 3m 30/09/2017h Innarun mpeiod Wye. andd 3 Months ends! m: minus piled Indl ended um L14" '01 _l_1_ mem WMMMM m from m 16,445 15,049 17,383 31,404 27,937 58,226 Pmflt m! Tax 7,006 3,680 6,232 11,! 7,953 14,972 M M Tu 6,665 3,102 4,498 9,707 5,412 10,9 Conelmm of And: I d Udall. A m 1 MM I In Mlllhn m Al II L5 a! 30/00/ /03/2018 (MI (W) a M, m II! Wit 41,791 38,157 b W mungroves 14,519 15,272 c W 14,3 13,853 d W W assets 13,273 12,816 2 lmstmans h m mm: 3,544 3,605 IWm I mm 1,021 1,104 i Loans 0 0 I (If. m AM 1,687 1,529 9 mm Tax mas [Net] 9,903 9,246 h (N! m assets 2,432 2,034 M for C111!!! tax [N6] 1, schw Noamnot 103,604 98,356 1 Quint M 25,516 23,853 It Flulad huh 2,748 I IW W I Mm 27,332 32% H cm lid 05h mm 3,415 5,357 wmmmmmmwmm,l11 7,782 v mans o 0 VI 08. tum W was I 3,448 : om: umnl was 7,. 6,744 WwM 75,952 82,005 Aids dmfled a hdd for SJ: MAI. m 1,! 180,653 I W AID LIA m a m shin capital 1,024 1,024 b (NIH ally ",0 86,421 cmmmmmdwm ",003 87,445 a W [mast 1,955 1,910 Subm m 91,041 99,355 2 Wmulmm Im 27,870 25,551 I 003 hand! '16 54D 524 DW 1,5 1,559 c Deferred h! mus [Net] 2,755 2,821 d ( Is NonCum! m Subm Nollfilm WM ,468 3 wiw mu WGlW 24,. 25,575 I Truth m 16,453 18,884 ll NE! W m 11,125 13,352 b M cum! m 1,7 1,387 c m 1,170 1,002 d Cum mm [Net] 1,5 520 w ww 5,736 60,720 mmmmmmflmsmmrsae u 110 mu. mum! Ann mums 130, ,653 Dy 0&1 ofi: m um,.m P. mu W,W 3, 2018

4 Zydus dedicatfgfl/g Hcealthacanginlwg ' November 3, 2018 Listing Department Code: BOMBAY STOCK EXCHANGE LIMITED P J Towers, Dalal Street, Fort, Mumbai Listing Department NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai Code: CADILAHC Re: Limited Review Refirt on the unaudited Financial Results for the quarter] half y_e_ar ended on September 30, 2018 Dear Sir, Please find attached herewith the limited review report on the unaudited financial results for the quarter / half year ended on September 30, 2018, by Deloitte Haskins & Sells LLP, the Statutory Auditors, reviewed by the Audit Committee and taken on record by the Board of Directors today i.e. November 3, 2018 pursuant to regulation 33[2][a] of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, Please receive the same in order and acknowledge the receipt of the same. Thanking you, Yours faithfully, F r, CADILA HEALTHCARE LIMITED UPEN H. SHAH COMPANY SECRETARY Encl.: As above Regd. Office : Zydus Tower, Satellite Cross Roads, Ahmedabad , India. Phone : (20 lines) CIN :L24230GJ1995PL

5 Deloitte Haskins & Sells LLP Chartered Accountants 196 Floor,ShapathV S G Highway Ahmedabad Gujarat, India Tel: Fax: INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF CADILA HEALTHCARE LIMITED We have reviewed the accompanying Statement of Standalone Unaudited Financial Results of CADILA HEALTHCARE LIMITED ('the Company") which includes a branch located at Philippines for the quarter and half year ended September 30, 2018 ("the Statement"), being submittedby the Companypursuantto the requirementof Regulation33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. ClWCFD/FAC/62/2016 dated July 5, This Statement,which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunderand other accounting principles generallyacceptedin India. Our responsibility is to issue a report on the Statement based on our review We conducted our review of the Statement in accordance with the Standard on Review Engagements(SRE) 2410 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity', issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement.a review is limited primarily to inquiries of Company personneland analytical proceduresapplied to financial dataand thus provides lessassurancethan an audit. We have not performed an audit and, accordingly, we do not expressan audit opinion. Basedon our review conductedas statedabove, nothing hascome to our attention that causesus to believe that the accompanying Statement, prepared in accordance with the aforesaid Indian Accounting Standardsand other accounting principles generally acceptedin India, hasnot disclosed the informationrequiredto bedisclosedin termsof Regulation33of the SEBI(Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by Circular No. CIR/CFD/FAC/62/2016 datedjuly 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm's Registration No W/W100018) AHMEDABAD, November 3, 2018 Gaurav J. Shah Partner (Membership No ) Page 1 of 1 Regd.Office:Indiabu!lsFinanceCentre,Tower3, 27 3Y Fioor,SenapatiBapatMarg,ElphinstoneRoad(West),Mumbai , Maharashtra,India. (LLP Identification No. AAB8737) Searchable PDF created by OCR.space

6 ' DeIOItte I Haskms & Sells Chartered Accountants S G Highway éflgfméms Tel: Fax: INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM FINANCIAL RESULTS TO THE BOARD OF DIRECTORS OF CADILA HEALTHCARE LIMITED 1. We have reviewed the accompanying Statement of Consolidated Unaudited Financial Results of CADILA HEALTHCARE LIMITED ( the Parent ) and its subsidiaries (the Parent and its subsidiaries together referred to as the Group ), and its share of the profit of its joint ventures for the quarter and half year ended September 30, 2018 ( the Statement") which includes the branch of the Group located at Philippines being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, This Statement, which is the responsibility of the Parent s Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 Interim Financial Reporting ( Ind AS 34 ), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on the Statement based on our review. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 Review of Interim Financial Information Performed by the Independent Auditor of the Entity, issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of Parent s personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and, accordingly, we do not express an audit opinion. The Statement includes the results of the following entities: Name of the Entities Parent Company Cadila Healthcare Limited Subsidiary Companies Alidac Pharmaceuticals Limited Dialforhealth India Limited Liva Pharmaceuticals Limited Sentynl Therapeutics Inc Violio Pharmaceuticals Limited Zydus Healthcare (USA) LLC Zydus Healthcare Limited Zydus Healthcare Philippines Inc. Zydus International Private Limited Zydus Lanka (Private) Limited Zydus Noveltech Inc. Zydus Pharmaceuticals (USA) Inc. Zydus Technologies Limited Zydus Wellness Limited Zydus Worldwide DMCC Page 1 of 3

7 Deloitte Haskins & Sells LLP Subsidiary Companies of Dialforhealth India Limited Dialforhealth Greencross Limited Dialforhealth Unity Limited Subsidiary Company of Violio Pharmaceuticals Limited Viona Pharmaceuticals Inc., USA (formerly known as Violio Pharmaceuticals Inc., USA) Subsidiary Companies of Zydus Healthcare Limited Acme Pharmaceuticals Private Limited Violio Healthcare Limited Subsidiary Companies of Zydus International Private Limited ZAHL B.V. Zydus Pharmaceuticals Mexico SA De CV Zydus Pharmaceuticals Mexico Services Company SA De C.V. Subsidiary Company of Zydus Noveltech Inc. Hercon Pharmaceuticals LLC Subsidiary Company of Zydus Pharmaceuticals (USA) Inc. Nesher Pharmaceuticals (USA) Inc Subsidiary of Zydus Wellness Limited M/s. Zydus Wellness Sikkim Subsidiary Companies of Zydus Worldwide DMCC Alidac Healthcare Myanmar Limited Etna Biotech S.R.L. Zydus Discovery DMCC Zydus France SAS Zydus Healthcare S.A. (Pty) Ltd. Zydus Netherland B.V Subsidiary Company of ZAHL B.V. ZAHL Europe B.V. Subsidiary Companies of Zydus Healthcare S.A. (Pty) Ltd. Script Management Services (Pty) Ltd. Simayla Pharmaceuticals (Pty) Ltd. Subsidiary Companies of Zydus Netherland B.V Laboratorios Combix S.L. Zydus Nikkho Farmaceutica Ltda. Joint Ventures Bayer Zydus Pharma Private Limited Zydus Hospira Oncology Private Limited Zydus Takeda Healthcare Private Limited 4. Based on our review conducted as stated above and based on the consideration of the reports of the other auditors referred to in paragraph 5 below, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in Page 2 of 3

8 Deloitte Haskins & Sells LLP accordance with the aforesaid Indian Accounting Standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. We did not review the interim financial results of 18 subsidiaries included in the consolidated unaudited financial results, whose interim financial results reflect total assets of Rs. 114,954 million as at September 30, 2018, total revenues of Rs. 17,847 million and Rs. 34,321 million for the quarter and half year ended September 30, 2018 respectively, total profit after tax of Rs. 952 million and Rs. 1,397 million and total comprehensive income of Rs. 949 million and Rs.1,394 million for the quarter and half year ended September 30, 2018 respectively, as considered in the consolidated unaudited financial results. These interim financial results have been reviewed by other auditors whose reports have been furnished to us by the Management and our report on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors. Our report on the statement is not modified in respect of this matter. 6. The consolidated unaudited financial results includes the interim financial information of 18 subsidiaries which have not been reviewed by their auditors, whose interim financial information reflect total assets of Rs. 18,262 million as at September 30, 2018, total revenues of Rs. 260 million and Rs. 526 million for the quarter and half year ended September 30, 2018 respectively, total loss after tax of Rs. 183 million and Rs. 263 million and Total comprehensive income of (Rs. 183 million) and (Rs. 263 million) for the quarter and half year ended September 30, 2018 respectively, as considered in the consolidated unaudited financial results. The consolidated unaudited financial results also includes the Group s share of profit after tax of Rs.179 million and Rs.360 million and total comprehensive income of Rs. 179 million and Rs.360 million for the quarter and half year ended September 30, 2018, respectively, as considered in the consolidated unaudited financial results, in respect of 3 joint ventures, based on their interim financial information which have not been reviewed by their auditors. According to the information and explanations given to us by the Management, such interim financial information are not material to the Group. Our report on the Statement is not modified in respect of our reliance on the interim financial information certified by the Management. For DELOITTE HASKINS & SELLS LLP Chartered Accountants (Firm s Registration No W/W100018) WGaurav J. Shah AHMEDABAD, November 3, 2018 Partner (Membership No ) Page 3 of 3

Statement of Profit and Loss for the year ended March 31, 2017 LKR- Thousands

Statement of Profit and Loss for the year ended March 31, 2017 LKR- Thousands Balance Sheet as at March 31, 2017 Particulars Note No. As at March 31 ASSETS: Non-Current Assets: Other Non-Current Financial Assets 1 15 15 7 7 15 15 7 7 Current Assets: Cash and Bank Balances 2 257